Ask the expert: Early-stage hormone receptor-positive, HER2-positive, and triple-positive breast cancer

Datopotamab deruxtecan (Datroway) is approved to treat hormone receptor-positive, HER2-negative metastatic breast cancer. It is an antibody-drug conjugate, a treatment that delivers chemotherapy directly to cancer cells.

Learn more about hormone receptor-positive metastatic breast cancer, which means the stage IV breast cancer is hormone-sensitive.

Read More

 | 6 Min. Read |  1

Tamoxifen is a type of hormonal therapy called a SERM, or selective estrogen receptor modulator, a medicine that prevents estrogen signals from getting to breast cancer cells.

Read More

 | 11 Min. Read |  8

Targeted therapies are treatments that target specific proteins or markers on or within cancer cells that help cancer cells grow. There are many different kinds of targeted therapy, including CDK 4/6 inhibitors.

Read More

 | 12 Min. Read |  1

Trastuzumab deruxtecan (Enhertu or T-DXd) is an antibody-drug conjugate that treats HER2-positive, HER2-low, or HER2-ultralow breast cancer that cannot be removed surgically or that has spread to another part of the body.

Inavolisib (Itovebi) is a new targeted therapy shown to reduce progression of certain hormone receptor-positive, HER2-negative, PIK3CA-positive metastatic breast cancers.

Read More

 | 8 Min. Read |  1

A FISH test is a lab test performed on tissue taken from a biopsy or breast cancer surgery, that can confirm breast cancer’s HER2 status if other test results are inconclusive.

Some of the most important breast cancer treatment decisions are based on immunohistochemistry (IHC) tests; hormone receptor status, HER2 status, and in some cases, PD-L1 status.

Ribociclib (Kisqali), a targeted therapy, is the second CDK 4/6 inhibitor to be approved by the FDA. It targets two specific kinases, or enzymes, that help tumor cells grow and divide.

Read More

 | 6 Min. Read |  1

Use this tool to find early-stage breast cancer clinical trials across the United States.

Read More

|  1